PLUS Therapeutics, Inc. (PSTV) is a clinical-stage pharmaceutical company with a focus on innovative oncology drugs. Originally named Cytori Therapeutics, the company changed its name to PLUS Therapeutics, Inc. in 2019. The company's headquarters are based in Austin, Texas.
PLUS Therapeutics is primarily involved in restructuring a clinically advanced, proprietary pipeline of novel therapies to treat a diverse spectrum of cancers. Their mission is to discover, develop and bring to market therapies that will help patients with life-threatening diseases. The company is committed to leveraging its extensive expertise and resources inside and outside oncology to bring forward effective and safe treatments for patients.
The company's core research and development programs are categorized into two series: Rhenium and RASio. The Rhenium program includes a patented nanoparticle-based radiotherapy Rhenium-186 NanoLiposome (186RNL) product candidate, which is currently in Phase 1 clinical trial for recurrent glioblastoma, a lethal brain cancer. The RASio program aims to inhibit the RAS signaling pathway, responsible for many types of cancer.
What sets PLUS Therapeutics apart is their pioneering approach to drug development. They reuse known drugs in a novel manner, reformulating them into new, patented medicine. The primary advantage is the lower development costs and the possibility to fast-track the product to the market due to the known safety profile of the active ingredients of the base drug.
Financially, PLUS Therapeutics, Inc. is categorized under the ticker PSTV in the NASDAQ stock exchange. As a public company, they are dedicated to creating shareholder's value through the aggressive advancement of their clinical programs and the opportune leverage of their intellectual property.
In summary, PLUS Therapeutics, Inc. is a trailblazer in the pharmaceutical industry by setting out to make a significant difference in patients' lives through the development and commercialization of targeted cancer treatments. Their pursuit of life-changing cancer treatments and commitment to patients' welfare, combined with innovative research and development, makes them an essential player in the global healthcare industry.